Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biomira, FDA agree on cancer trial design
The agreement between Biomira and the FDA concerns the design of the phase III trial and outlines definitive clinical objectives and data analyses considered necessary to support regulatory
The agreement between Biomira and the FDA concerns the design of the phase III trial and outlines definitive clinical objectives and data analyses considered necessary to support regulatory
“We attribute these strong safety and efficacy results to our unique formulation of gabapentin which is based on our AcuForm drug delivery technology,” said Carl Pelzel, executive vice
The purchase price will increase with contingent payments of up to $3.50 per share based on the achievement of future product milestones. “The acquisition of Valera firmly establishes
EvaMist is a transdermal spray that delivers estradiol, a naturally occurring estrogen, for the treatment of hot flashes in women. Vivus reported positive results from its phase III
Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as loss of libido, adverse changes in body composition, irritability and poor
According to Solvay, this means that the formal processing and review period both begin. This event has triggered a milestone payment of $25 million from Wyeth, Solvay's co-development
The agreement will include including Epix's novel 5-HT4 partial agonist program, PRX-03140, in early-stage clinical development for the treatment of Alzheimer's disease. The alliance will be conducted through
In addition, the early analysis indicates a trend toward improvement in overall survival in the Avastin plus interferon arm. “We are pleased with the results demonstrating improvement in
Velcade is an FDA approved treatment for relapsed or refractory multiple myeloma. The study results demonstrate that patients who received a combination of Doxil and Velcade had 45%
The acquisition would strengthen Johnson & Johnson's position as the world's largest supplier of consumer health-care and over-the-counter medicines. The Commission said the acquisition did raise some concerns